NNovo Nordisk Read More Menopause Heart Data, Oral Pill Revenue Double, and a Parkinso2026-05-13 Novo Nordisk: Wegovy CV risk reduction 42% in perimenopausal women, oral pill sales double forecasts, high-dose 27.7% weight…